CAS 145903-06-6: 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine

JTV-519 hemifumarate is a calcium sensitizer, which is a pharmaceutical agent designed to improve cardiac contractility. It is derived from a synthetic process focusing on modulating calcium dynamics within cardiac cells. By binding to and stabilizing the ryanodine receptor (RyR2), JTV-519 hemifumarate enhances calcium release from the sarcoplasmic reticulum during the cardiac cycle. This action leads to an increase in the sensitivity of cardiac myofilaments to calcium without increasing intracellular calcium concentration, thereby improving myocardial contractility without the pro-arrhythmic effects associated with increased calcium transients. The primary applications of JTV-519 hemifumarate include the treatment and management of heart failure and other cardiac disorders characterized by impaired contractility. By enhancing cardiac muscle function, it aids in restoring adequate cardiac output, offering a potential therapeutic approach for patients with heart failure symptoms. Furthermore, due to its mechanism of action, JTV-519 hemifumarate is a subject of ongoing research exploring its potential benefits in limiting arrhythmias and providing protective cardiac effects in various experimental models.

JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic